Georges Lacaud
Stem Cell Biology Group Leader
Georges is a Senior Group Leader at the CRUK Manchester Institute where he leads the Stem Cell Biology group. His research focuses on the regulation of normal haematopoiesis to better understand the development of leukaemia and other blood cancers.
About Professor Georges Lacaud
Georges Lacaud graduated as a biotechnology engineer from the European Biotechnology School of Strasbourg (ESBS) in Strasbourg, France. He obtained his PhD from the University Louis Pasteur of Strasbourg, France and then undertook a postdoctoral fellowship at the National Jewish Medical Center in Denver, Colorado, USA studying early lymphoid cell development in Prof. Gordon Keller’s lab.
Georges next moved to the Mount Sinai School of Medicine in New York, NY, USA where he worked on early hematopoietic development.
In 2003, he joined the CRUK Manchester Institute as a junior group leader. He is now a senior group leader and heads the Stem Cell Biology group. Georges was awarded a Professorship in Stem Cell Biology at The University of Manchester in 2018.
Groups
Qualifications
- PhD in Molecular & Cellular Biology | 1994 | University of Strasbourg, France
- Engineer | 1988 | University of Strasbourg, France
Interests
- Blood cancer
- Developmental haematopoiesis
- Cellular (immuno)therapies
- Reprogramming
Research Projects
Publications
- Murine AGM single-cell profiling identifies a continuum of hemogenic endothelium differentiation marked by ACE
- The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency
- The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation
- GFI1 proteins orchestrate the emergence of haematopoietic stem cells through recruitment of LSD1
Why I work at CRUK MI
“I am delighted to work at here at the Institute because of its collaborative environment, scientific freedom, and access to cutting-edge resources. Interacting daily with a team of brilliant and dedicated scientists is truly inspiring.”
Visit Research Group
Our team is focused on uncovering the mechanisms underlying leukaemia development and maintenance, with the goal of identifying and validating new therapeutic targets. Additionally, we aim to understand the processes governing normal haematopoietic development, enabling us to replicate this in vitro for the generation of therapeutic immune cells.
To achieve these objectives, we are employing advanced technologies, including single-cell multi-omics, spatial transcriptomics, CRISPR screening, mass spectrometry, bioinformatics, medicinal chemistry, mouse models, organoid cultures, and patient-derived samples.
Get in touch
https://doi.org/10.1186/s12943-024-02157-x
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer
12 November 2024
Institute Authors (1)
Amaya Viros
Labs & Facilities
Genome Editing and Mouse Models
Research Group
Skin Cancer & Ageing
12 November 2024
https://doi.org/10.1186/s13045-024-01610-0
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency
8 October 2024
Institute Authors (6)
Georges Lacaud, Mathew Sheridan, Michael Lie-a-ling, Liam Clayfield, Jessica Whittle, Jingru Xu
Research Group
Stem Cell Biology
8 October 2024
/wp-content/uploads/2024/11/Annual-Report-2023.pdf
2023 Annual Report
13 September 2024
13 September 2024
https://doi.org/10.1126/science.adh7954
Vitamin D regulates microbiome-dependent cancer immunity
25 April 2024
Institute Authors (1)
Evangelos Giampazolias
Research Group
Cancer Immunosurveillance
25 April 2024
https://doi.org/10.1038/s41684-024-01363-w
Streamlining mouse genome editing by integrating AAV repair template delivery and CRISPR-Cas electroporation
10 April 2024
Institute Authors (1)
Natalia Moncaut
Labs & Facilities
Genome Editing and Mouse Models
10 April 2024
https://www.biorxiv.org/content/10.1101/2023.12.13.568969v1
A novel human model to deconvolve cell-intrinsic phenotypes of genetically dysregulated pathways in lung squamous cell carcinoma
14 December 2023
Institute Authors (3)
Carlos Lopez-Garcia, Caroline Dive, Anthony Oojageer
Research Group
Translational Lung Cancer Biology
14 December 2023
Our vision for world leading cancer research in the heart of Manchester
We are a leading cancer research institute within The University of Manchester, spanning the whole spectrum of cancer research – from investigating the molecular and cellular basis of cancer, to translational research and the development of therapeutics.
Our collaborations
Bringing together internationally renowned scientists and clinicians
Scientific Advisory Board
Supported by an international Scientific Advisory Board
Careers that have a lasting impact on cancer research and patient care
We are always on the lookout for talented and motivated people to join us. Whether your background is in biological or chemical sciences, mathematics or finance, computer science or logistics, use the links below to see roles across the Institute in our core facilities, operations teams, research groups, and studentships within our exceptional graduate programme.
Institute life in Manchester
We strive to make our community a welcoming, caring and enthusiastic one, fuelling ambition with opportunities for training and mentoring to help us all achieve our personal and professional goals.
“We are so pleased to have received the funding to enable us to test our hypothesis in the lab. If we can create a new medicine that can precisely target a specific type of cell within the tumour, and restore anti-cancer immune responses, this will be a game-changer for oesophageal cancer patients “
Sara Valpione
Former Institute Clinical Fellow and now Clinician in Residence within the CRUK National Biomarker Centre
“My charity bake sales – known as “David’s Great British Bake Off” – are always a hit, home baked products taste so much better than shop bought and are greatly appreciated by staff!”
David Jenkins
Purchasing Officer
“We’ve seen some remarkable responses, with an improvement for some patients within days. This is an early phase trial so there’s a lot more work to do. But the data we have so far is very encouraging and could help many thousands of people in the future”
Tim Somervaille
Senior Group Leader
“It is a pleasure to introduce my team who work to deliver our research goals. We work in a friendly and collaborative environment, supporting each other’s projects. “
Amaya Virós
CRUK Advanced Clinician Scientist Fellow
“We are so pleased to have received the funding to enable us to test our hypothesis in the lab. If we can create a new medicine that can precisely target a specific type of cell within the tumour, and restore anti-cancer immune responses, this will be a game-changer for oesophageal cancer patients “
Sara Valpione
Former Institute Clinical Fellow and now Clinician in Residence within the CRUK National Biomarker Centre
“My charity bake sales – known as “David’s Great British Bake Off” – are always a hit, home baked products taste so much better than shop bought and are greatly appreciated by staff!”
David Jenkins
Purchasing Officer
“We’ve seen some remarkable responses, with an improvement for some patients within days. This is an early phase trial so there’s a lot more work to do. But the data we have so far is very encouraging and could help many thousands of people in the future”
Tim Somervaille
Senior Group Leader
“It is a pleasure to introduce my team who work to deliver our research goals. We work in a friendly and collaborative environment, supporting each other’s projects. “
Amaya Virós
CRUK Advanced Clinician Scientist Fellow